Efficacy of Topical Cyclosporine 0.05% the Treatment of Vernal Keratoconjunctivitis

2020 ◽  
Vol 12 (1) ◽  
pp. 39-47
Author(s):  
Kumudini Subedi ◽  
Binita Sharma ◽  
Sabina Shrestha
Keyword(s):  
Chronic Disease ◽  
Symptom Score ◽  
Marked Improvement ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Loading Dose ◽  
Beneficial Effects ◽  
Similar Sign ◽  
Symptoms And Signs

Introduction: Vernal Keratoconjunctivitis is a chronic bilateral seasonally exacerbated allergy affecting the conjunctiva and cornea of children. As technology has advanced, newer medications have been developed for the control of the disease. Purpose: To assess the effectiveness of an immunomodulator, cyclosporine, in the treatment of vernal keratoconjunctivitis. Materials and methods: Fifty patients of moderate, severe to very severe vernal keratoconjunctivitis were selected for the study. They were given cyclosporine 0.05% eye drops in loading dose followed by gradual tapering. Symptoms and signs were recorded at presentation, after two weeks, after four weeks, after two months and after three months. Results: Vernal keratoconjunctivitis, being a chronic disease showed marked improvement with immunomodulator therapy. There was significant improvement in the symptom and sign score initially, at the first follow up itself with symptom score reduction from median of mean of 2.4 to 0.6 (p=0.00) and a similar sign score reduction from 1.75 to 0.625 (p=0.00). There was gradually more improvement as therapy continued and the beneficial effects were maintained till the end point of the study at three months where median of mean symptom score was 0.4 (p=0.00) and similar sign score of 0.375 (p= 0.000). Conclusion: Topical cyclosporine proved to be an effective and safe treatment strategy to treat cases of moderate, severe and very severe vernal keratoconjunctivitis.

scholarly journals Sweet disaster: use of honey-based eye drops as an alternative treatment for vernal keratoconjunctivitis

2019 ◽  
Vol 1 (2) ◽  
pp. 133-138
Author(s):  
Kenneth Teow Kheng Leong ◽  
Rebecca Jennifer Mary Louis ◽  
Lai Yin Peng ◽  
Rohanah Alias ◽  
Safinaz Mohd Khialdin
Keyword(s):  
Visual Acuity ◽  
Anterior Chamber ◽  
Alternative Treatment ◽  
Marked Improvement ◽  
Traditional Healer ◽  
Fungal Keratitis ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
The Past

A 16-year-old boy with underlying bronchial asthma, vernal keratoconjunctivitis, and bilateral eye steroid-induced glaucoma presented with right eye itchiness, redness, and progressive painful blurring of vision for the past 3 weeks. His mother had been treating him with honey-based eye drops purchased from an unregistered source/traditional healer. On presentation his right visual acuity was counting fingers, the cornea was hazy, and a small central stromal abscess with a large endothelial plaque was seen in the anterior chamber. He was treated for right eye fungal keratitis and subsequently admitted for intensive treatment. He showed marked improvement and was discharged. His final vision on follow-up was 6/15.

Longitudinal Follow-Up of Death Anxiety and Psychophysical-Symptom Experience of Participants in the Silent Mentor Program

2021 ◽  
pp. 003022282110436
Author(s):  
Li Ping Wong ◽  
Sik Loo Tan ◽  
Haridah Alias ◽  
Thiam Eng Sia ◽  
Aik Saw
Keyword(s):  
Symptom Score ◽  
Death Anxiety ◽  
Psychological Symptom ◽  
Physical Symptom ◽  
Mentor Program ◽  
Symptom Experience ◽  
Beneficial Effects ◽  
Attitude Towards Death ◽  
T1 And T2

This study assessed death anxiety (Death Anxiety Questionnaire, DAQ) and psychophysical- (psychological and physical) symptom experience following cadaveric dissection among the Silent Mentor Program (SMP) participants before thawing (T1), after the suturing, dressing and coffining session (T2), and one month post-program (T3). There was a significant decline in the total DAQ score comparing T1 and T2 ( t = 7.69, p < 0.001) and T2 and T3 ( t = 5.00, p < 0.001) and T1 and T3 (t = 10.80, p < 0.001). There was a significant reduction in total psychological-symptom score comparing T1 and T2 ( t = 4.92, p < 0.001) and between T1 and T3 ( t = 4.85, p < 0.001). However, for the physical-symptom experience, a significant increase in the physical-symptom score between T1 and T2 ( t = –3.25, p = 0.001) was reported but the scores reduced significantly one month after the program (T2–T3; t = 4.12, p < 0.001). The mentoring concept of the SMP program has beneficial effects on improving attitude towards death and psychophysical-symptom experience associated with cadaver dissection.

scholarly journals Comparative evaluation of efficacy and safety of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.1% ophthalmic solution in patients with vernal keratoconjunctivitis

2021 ◽  
Vol 10 (5) ◽  
pp. 552
Author(s):  
Priya Gupta ◽  
Seema Baishnab ◽  
Parveen Rewri
Keyword(s):  
Clinical Symptoms ◽  
Ophthalmic Solution ◽  
Histamine Receptor ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Efficacy And Safety ◽  
Open Label ◽  
Male Predominance ◽  
Significant Difference ◽  
Symptoms And Signs

Background: Vernal keratoconjunctivitis (VKC) is a chronic, seasonally exacerbated, allergic ocular inflammation. It affect children and young adults and has male predominance. The first line of treatment often used is dual acting drugs like olopatadine and bepotastine. It combine the immediate histamine receptor antagonism, coupled with mast cell stabilization with other anti-inflammatory properties. The present study was conducted to compare the efficacy and safety of olopatadine 0.1% and bepotastine 1.5% eye drops in VKC patients.Methods: This was a prospective, open label, randomized and comparative clinical study conducted for 21 days. 65 patients of VKC of 5-15 years of either sex were randomized in two study arm. Arm A, given bepotastine 1.5% and arm B, given olopatadine 0.1% twice daily for 21 days. Symptoms and signs scoring of VKC along with safety assessment were recorded on baseline and at time of follow up on 7th day and 21st day.Results: After 3 weeks of drug therapy, patients in both arms showed improvement in the symptoms and signs scoring of VKC. There was no statistically significant difference between the two treatment arms. However, improvement in clinical parameters particularly ocular itching, which is the main complaint of patients with VKC was more in bepotastine arm as compared to olopatadine treated arm. Both the drugs were well tolerated without any serious adverse effect.Conclusions: Both olopatadine and bepotastine were found to be effective in alleviating the clinical symptoms and signs of VKC. However, bepotastine performed better in reducing ocular itch than olopatadine.

scholarly journals The Efficacy of Topical 0.03% Tacrolimus Dermatologic Ointment in Treatment of Vernal Keratoconjunctivitis

2021 ◽  
Vol 2 (4) ◽  
pp. 6
Author(s):  
Muhammad Adnan ◽  
Amena Masrur ◽  
Furqan Ahmed Khan ◽  
Ali Tayyab
Keyword(s):  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Slit Lamp ◽  
Night Time ◽  
The Mean ◽  
Preservative Free

Objective: To determine the efficacy of 0.03% Tacrolimus dermatologic ointment in the treatment of Vernalkeratoconjunctivitis.Study Design: Cross-sectional.Place and Duration of Study: The study was conducted at Eye Donors Association Hospital, Wah Cantonmentfrom August 2019 to January 2020.Materials and Methods: 103 diagnosed patients ofvernal keratoconjunctivitis, aged 3-16 years, were includedin this study. They were treated with 0.03% Tacrolimus dermatologic ointment,applied in the inferior fornixonce at night time, for a period of two months. In addition, these patients were also prescribeda topical antihistamine(0.05 % ketotifen eye drops 3 times a day)and preservative free artificial tearsfor symptomatic relief.The patients were evaluated at 4 and 8 weeks after the initiation of treatment. At each follow up the clinicalsigns were assessed on a slit lamp biomicroscope by a single observer and recorded on a standardized gradingsheet.Results: Out of 103 patients, 66% were male and mean age was 9 years (range 3-16 years). The mean baselinescores showed a statistically significant decrease, with the exception of palpebral follicles & limbal Trantas dotsafter 8 weeks of treatment.Conclusion: 0.03% Tacrolimus dermatologic ointment was found to be safe and effective in the treatment ofvernal kerato-conjunctivitis.

scholarly journals A prospective comparative study to evaluate the efficacy and safety of olopatadine eye drops and bepotastine eye drops in subjects of vernal kerato conjunctivitis

2020 ◽  
Vol 9 (5) ◽  
pp. 706 ◽  
Author(s):  
Amatur R. Malahat ◽  
Sudhakar Kodudula ◽  
Vijaya L. Gali
Keyword(s):  
Comparative Study ◽  
Symptomatic Relief ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Efficacy And Safety ◽  
Conjunctival Hyperaemia ◽  
Parallel Group ◽  
Significant Difference ◽  
Ocular Discomfort

Background: Vernal keratoconjunctivitis (VKC) is an allergic eye disease that especially affects young boys. Both olopatadine and bepotestine are dual acting drugs that provide rapid symptomatic relief coupled with the long-term disease-modifying benefit. The present study is conducted to compare the efficacy and safety of olopatadine eye drops and bepotastine eye drops in patients of vernal keratoconjunctivitis.Methods: A prospective, randomized, parallel-group, comparative study is conducted over a period of 4 weeks on paediatric patients with VKC. 50 patients are recruited and randomized into two treatment groups. They received the assigned drugs for 4 weeks and are called for follow up at the end of 1st week, 4th week and 12th week. At each follow-up, patients are examined and the clinical parameters are graded.Results: This study shows that both olopatadine and bepotastine are equally efficacious. Bepotastine provided quicker relief to symptoms of watering, ocular discomfort and conjunctival hyperaemia. Number of responders are also more in the bepotastine group. Absolute eosinophilic count improved with both the drugs but there is no statistically significant difference between them. Both drugs showed good safety profile. However, 24% patients reported aversion to bitter taste with bepotastine. There is no treatment related severe adverse effects in both the groups.Conclusions: Both olopatadine and bepotastine are effective in treating vernal keratoconjunctivitis. However, bepotastine performed better in reducing tearing, ocular discomfort and conjunctival hyperaemia.

scholarly journals A Study on the Use of Topical Bepotastine Besilate Ophthalmic Solution (Bbos) 0.15% in the Treatment of Vernal Keratoconjunctivitis at Tertiary Care Hospital

2021 ◽  
Vol 70 (1) ◽  
Author(s):  
Jyoti Dahiya ◽  
Vivek Sharma ◽  
Sumit Sachdeva ◽  
Srishti Srishti
Keyword(s):  
Clinical Symptoms ◽  
Tertiary Care ◽  
Ophthalmic Solution ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Care Hospital ◽  
Open Label ◽  
Randomized Clinical Study ◽  
Significant Difference ◽  
Symptoms And Signs

The aim of this study is to Evaluation of Efficacy and Safety of Bepotastine Besilate 0.15% Ophthalmic Solution in Patients of Vernal Keratoconjunctivitis (VKC). This was a prospective, open label and randomized clinical study. Fifty patients of vernal keratoconjunctivitis between 6 to 20 years of age of either sex willing to give informed consent were enrolled in the study. Patients received Bepotastine besilate (0.15%) eye drops twice daily for 8 weeks. Symptoms scoring and signs scoring of VKC were recorded on baseline and at the time of follow up at 4 and 8 weeks. Safety assessments were also done in the drug group during the study period for any serious adverse effects. After the 2 months of drug therapy, patients showed improvement in the symptoms and signs scoring of Vernal keratoconjunctivitis. There was statistically significant difference between the treatment group at 4th and 8th week. The drugs were well tolerated without any serious adverse effect. Bepotastine besilate ophthalmic solution were found to be effective in alleviating the clinical symptoms and signs of VKC.

scholarly journals Retrospective Review on the Use of Topical Cyclosporin A 0.05% for Paediatric Allergic Conjunctivitis in Hong Kong Chinese

2014 ◽  
Vol 2014 ◽  
pp. 1-5
Author(s):  
Macy M. S. Wu ◽  
Gordon S. K. Yau ◽  
Jacky W. Y. Lee ◽  
Amy L. Wong ◽  
Victor T. Y. Tam ◽  
...  
Keyword(s):  
Cyclosporin A ◽  
Allergic Conjunctivitis ◽  
Hong Kong Chinese ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Ocular Symptoms ◽  
Severity Scores ◽  
Symptom Scores ◽  
The Mean

Purpose. To evaluate the efficacy of using topical cyclosporin A 0.05% (Restasis) for the treatment of paediatric allergic conjunctivitis.Methods. This retrospective study included consecutive cases of paediatric allergic conjunctivitis treated with Restasis between 2010 and 2013. Subjects with follow-up time less than 3 months after using Restasis were excluded. Itch severity score, symptom score, and sign score were compared before (baseline) and 3 months after using Restasis.Results. In 27 eyes of 14 patients (mean age10.8±3.2years), 44.4% had allergic conjunctivitis, 33.3% had vernal keratoconjunctivitis, and 22.2% had atopic keratoconjunctivitis. The mean duration of ocular symptoms was20.4±13.2months. 92.6% of subjects were using steroid eye drop before Restasis. After 3 months of topical Restasis, there were statistically significant reductions in the symptom, sign, and itch severity scores compared with baseline (allP≤0.001) and 78.6% of subjects were able to be tapered off steroid eye drops.Conclusion. Topical Restasis was effective and safe in significantly reducing ocular itchiness, sign, and symptom scores at 3 months after use in paediatric allergic ocular conditions.

scholarly journals A Double Blind Clinical Trial on the Efficacy of Honey Drop in Vernal Keratoconjunctivitis

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Ali Salehi ◽  
Solmaz Jabarzare ◽  
Mohammadreza Neurmohamadi ◽  
Soleiman Kheiri ◽  
Mahmoud Rafieian-Kopaei
Keyword(s):  
Clinical Trial ◽  
Vernal Keratoconjunctivitis ◽  
Control Group ◽  
Placebo Control ◽  
Eye Drops ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Placebo Control Group ◽  
Double Blind Clinical Trial

Purpose. This trial was designed to evaluate the efficacy and safety of topical honey eye drops in patients with diagnosed VKC.Methods. This clinical trial was conducted on 60 patients with diagnosed VKC. The patients were selected and randomly allocated between two groups of 30. Patients in two groups received honey eye drop (60% in artificial tear) or placebo, other than cromolyn and fluorometholone 1% eye drops, to be used topically in each eye, four times per day. The patients were examined with slit lamp and torch at baseline and the follow-up visits on the 1st, 3rd, and 6th months of the study for redness, limbal papillae, and intraocular pressure.Results. Out of 60 patients who completed the study, 19 patients (31.7%) were female. There was significant increase in eye pressure and reduction in redness as well as limbal papillae, following the consumption of the honey drop in honey group compared to placebo control group(P<0.05). At the end of trial, one patient in honey group and 7 ones in placebo group had limbal papillae(P<0.05).Conclusion. Topical honey eye drops, when used along with Cromolyn and Fluorometholone eye drops, might be beneficial for the treatment of VKC.

scholarly journals Combination of 0.05% Azelastine and 0.1% Tacrolimus Eye Drops in Children With Vernal Keratoconjunctivitis: A Prospective Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Minjie Chen ◽  
Anji Wei ◽  
Bilian Ke ◽  
Jun Zou ◽  
Lan Gong ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Pediatric Patients ◽  
Therapy Group ◽  
Clinical Signs ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Combination Therapy Group ◽  
Monotherapy Group ◽  
Conjunctival Hyperemia

Aims: To compare the efficacy of the combination of 0. 05% azelastine and 0.1% tacrolimus eye drops with 0.1% tacrolimus monotherapy in pediatric patients with vernal keratoconjunctivitis (VKC).Methods: Prospective study. Seventy-six patients with VKC were randomized 1:1 into monotherapy group with 0.1% tacrolimus or combination therapy group with 0.1% tacrolimus and 0.05% azelastine. The Ocular Surface Disease Index (OSDI) scores and the signs of conjunctival hyperemia, corneal involvement, and palpebral conjunctiva papillae were assessed at baseline and at 1, 2, and 6 weeks after treatment.Results: Two groups were comparable in age, sex, duration of VKC, OSDI, and clinical signs of VKC at baseline. Significant improvements in OSDI score and clinical signs were observed in both groups at all follow-up visits (all p &lt; 0.001), compared with baseline. The combination therapy group showed a larger decrease in OSDI score from baseline (10.30 ± 0.9) compared with monotherapy group (7.30 ± 0.7, p =0.0085) at 1 week. Greater improvements in conjunctival hyperemia and conjunctival papillae were identified in the combination therapy group, compared with in the monotherapy group, at all follow-up visits (all p &lt; 0.05). The corneal involvement scores in the combination group is significantly lower than the monotherapy group at 2 weeks after the treatment (p = 0.0488). No severe adverse effect was found in either group during the study.Conclusions: Compared with a monotherapy of 0.1% tacrolimus, the combination of 0.05% azelastine and 0.1% tacrolimus eye drops lead to faster and greater improvements in clinical signs and symptoms of vernal keratoconjunctivitis in pediatric patients.

Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study

2021 ◽  
Vol 18 ◽  
Author(s):  
Francine Rubião ◽  
Alan Cezar Faria Araújo ◽  
João Bernardo Sancio ◽  
Bárbara Silva Nogueira ◽  
Juçara Ribeiro Franca ◽  
...  
Keyword(s):  
Ocular Hypertension ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
T Test ◽  
Controlled Study ◽  
Therapeutic Drug ◽  
Eye Drops ◽  
Open Angle ◽  
Drug Concentrations

Background: The most common treatment for primary open-angle glaucoma (POAG) is the daily use of eye drops. Sustained-release drug delivery systems have been developed to improve patient adherence by achieving prolonged therapeutic drug concentrations in ocular target tissues while limiting systemic exposure. The purpose of this study is to compare the efficacy and safety of bimatoprost inserts with bimatoprost eye drops in patients with POAG and ocular hypertension (OH). Methods: We include OH and POAG patients aged between 40 and 75 years-old. Both OH and POAG patients had intraocular pressure (IOP) greater than 21 and ≤30 mmHg at 9:00 am without glaucoma medication and normal biomicroscopy. Five normal patients with IOP≤14 mmHg constitute the control group. A chitosan-based insert of bimatoprost was placed at the upper conjunctival fornix of the right eye. In the left eye, patients used one drop of LumiganTM daily at 10:00 pm. For statistical analysis, we used a two-way analysis of variance (ANOVA), Student t-test, and paired t-test. Results: Sixteen POAG and 13 OH patients with a mean age of 61 years were assessed. In both eyes, IOP reduction was similar during three weeks of follow-up (19.5±2.2 mmHg and 16.9±3.1 mmHg), insert, and eye drop, respectively; P=0.165). The percentage of IOP reduction in the third week was 30% for insert and 35% for eye drops (P=0.165). No intolerance or discomfort with the insert was reported. Among the research participants, 58% preferred the use of the insert while 25% preferred eye drops, and 17% reported no preference. Conclusions: Bimatoprost-loaded inserts showed similar efficacy to daily bimatoprost eye drops during three weeks of follow up, without major side effects. This might suggest a possible change in the daily therapeutic regimen for the treatment of POAG and OH.

Sign in / Sign up

Export Citation Format

Share Document